Dr. Dixon on Belinostat Plus CHOP in Patients with T-Cell Lymphoma

In this OncLiveTV video, “Graham Dixon, PhD, chief scientific officer, Onxeo, director, R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.”

Learn more about lymphoma here: http://bit.ly/1UwWKe6

Tagged , , .

Andreia has a degree in New Communication Technologies and experience in social media, design and tech. She is eager to find new ways to communicate and explore her curiosity about science and technology.

Leave a Comment

Your email address will not be published. Required fields are marked *